Evdoxia Kyriazopoulou, Yehudit Hasin‐Brumshtein, Uros Midic, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Myrto Astriti, Archontoula Fragkou, Aggeliki Rapti, Eleonora Taddei, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Zoi Alexiou, Francesco Castelli, Francesco Saverio Serino, Petros Bakakos, Emanuele Nicastri, Vasiliki Tzavara, Sofa Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios Kotsis, Dionysios G. Tsoukalas, Carlo Selmi, Alexandra Konstantinou, Michael Samarkos, Michael Doumas, Aikaterini Masgala, Konstantinos Pagkratis, Aikaterini Argyraki, Karolina Akinosoglou, Styliani Symbardi, Mihai G. Netea, Periklis Panagopoulos, George N. Dalekos, Oliver Liesenfeld, Timothy E. Sweeney, Purvesh Khatri and Evangelos J. Giamarellos-Bourboulis
Critical Care 2024 Mar 12;28(1):73
DOI: 10.1186/s13054-024-04852-zDownload pdf 🡇
Funding
The SAVE-MORE trial was funded in part by the Hellenic Institute for the Study of Sepsis (HISS) and in part by Swedish Orphan Biovitrum AB (Sobi). RNA sequencing was funded by Inflammatix as part of the SUBSPACE Consortium.
Keywords: Anakinra; COVID-19; Endotypes; Viral sepsis
Related Study: SAVE-MORE